Building Your Multidisciplinary Care Team
At a Glance
Children with TRMA need coordinated, long-term care because the condition can affect blood, blood sugar, hearing, vision, and heart rhythm. A lead clinician, shared records, regular communication, and a written emergency plan help the team respond safely.
Because Thiamine-Responsive Megaloblastic Anemia (TRMA) affects several different parts of the body, your child’s care cannot be handled by just one doctor. Instead, you will work with a multidisciplinary care team—a group of specialists who coordinate their efforts to manage every aspect of the condition [1][2].
The Core Members of Your Team
Each specialist on your team has a specific role in monitoring and protecting your child’s health:
- Clinical Geneticist or Metabolic Specialist: Often the “anchor” of the team, this doctor interprets the SLC19A2 genetic results, provides counseling on how the condition is inherited, and helps coordinate the overall medical plan [3][4].
- Pediatric Hematologist: This specialist monitors your child’s blood counts (CBC). They track how well the thiamine is working to correct the anemia and ensure that other blood cells, like platelets and white cells, remain at healthy levels [5][6].
- Pediatric Endocrinologist: Responsible for managing the diabetes component of TRMA. They monitor blood sugar and HbA1c levels, adjust insulin if needed, and provide “sick-day rules” to prevent emergencies like diabetic ketoacidosis [7][8].
- Audiologist and ENT Specialist: These experts monitor for sensorineural hearing loss. They perform regular hearing tests and, if hearing aids are no longer enough, they evaluate whether your child is a candidate for a cochlear implant [9][10].
- Ophthalmologist: A specialized eye doctor who checks for changes in the retina or damage to the optic nerve. They use baseline exams and regular follow-ups to catch any vision changes as early as possible [11][12].
- Pediatric Cardiologist: Because TRMA can affect the heart’s electrical rhythm, this specialist uses electrocardiograms (ECG) to monitor for irregular heartbeats or unique heart-wave patterns associated with the condition [13][14].
Essential Support Professionals
Medical care is only one part of managing TRMA. Your team should also include:
- Genetic Counselor: Explains recurrence risks and coordinates family testing.
- Diabetes Educator: Provides practical training on checking glucose and administering insulin safely.
- Primary Pediatrician: Acts as a local medical home and rare-disease coordinator.
- Social Worker or Mental-Health Professional: Helps navigate insurance, resources, and emotional support.
- Speech-Language Pathologist or Deaf-Education Support: Essential for communication access and hearing-related school accommodations.
Organizing for Success
When a disease is this rare, you are a vital partner supported by your clinical lead to ensure every doctor has the most current information. Creating a “Care Binder” or a centralized digital folder is one of the most effective ways to support your child’s team [15].
What to bring to your first specialist visits:
- Genetic Reports: The official document confirming the SLC19A2 mutation. This is the most important piece of paper for every specialist to see [3].
- Blood Work History: A folder of past CBC results and transfusion records so the hematologist can see how your child’s blood has changed over time [6].
- Diabetes Logs: Records of daily blood sugar readings, insulin doses (if any), and HbA1c results [16].
- Medication List: A clear list of your child’s daily thiamine dose and any other medications or supplements [1].
- Specialist Reports: Copies of the most recent hearing tests, eye exams, and heart screenings [15].
Coordinating Rare Care
Because TRMA is so rare, your specialists may not have another patient with this diagnosis. A successful team is one where the doctors are willing to learn alongside you and consult with outside experts [1]. It is helpful to ask your team to identify a “lead clinician”—often the geneticist or your primary pediatrician—who will be the main point of contact for coordinating care and managing emergencies [2][1]. Having a clear emergency care plan in writing is essential for sharing with schools, ER staff, and other caregivers [17]. This one-page portable letter should include the diagnosis, current thiamine dose, relevant diabetes plan, a missed or vomited-dose plan, treating contacts, and symptoms that warrant emergency evaluation.
Common questions in this guide
Who should coordinate my child's TRMA care team?
Which specialists typically care for a child with TRMA?
What should I bring to TRMA specialist appointments?
How can my child's doctors share information safely?
What should be in a TRMA emergency care plan?
Should a rare-disease specialist center be involved in TRMA care?
Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives.
Tumienė B, Del Toro Riera M, Grikiniene J, et al.
Journal of multidisciplinary healthcare 2022; (15()):553-566 doi:10.2147/JMDH.S251863.
PMID: 35387391 - 2
Developing a taxonomy of care coordination for people living with rare conditions: a qualitative study.
Walton H, Simpson A, Ramsay AIG, et al.
Orphanet journal of rare diseases 2022; (17(1)):171 doi:10.1186/s13023-022-02321-w.
PMID: 35443702 - 3
Whole-Exome Sequencing Revealed a Pathogenic Nonsense Variant in the SLC19A2 Gene in an Iranian Family with Thiamine-Responsive Megaloblastic Anemia.
Mohsen-Pour N, Naderi N, Ghasemi S, et al.
Laboratory medicine 2022; (53(6)):640-650 doi:10.1093/labmed/lmac040.
PMID: 35686496 - 4
The increasing role of genetic counseling in pediatric oncology.
Clark ME, McGee RB, Zelley K
Current opinion in pediatrics 2026; (38(1)):65-72 doi:10.1097/MOP.0000000000001525.
PMID: 41451551 - 5
Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report.
Katipoğlu N, Karapinar TH, Demir K, et al.
Archivos argentinos de pediatria 2017; (115(3)):e153-e156 doi:10.5546/aap.2017.eng.e153.
PMID: 28504500 - 6
Pancytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Moulin V, Grandoni F, Castioni J, Lu H
BMJ case reports 2018; (2018()) doi:10.1136/bcr-2018-225035.
PMID: 29903777 - 7
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.
Habeb AM, Flanagan SE, Zulali MA, et al.
Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.
PMID: 29450569 - 8
First 2 cases with thiamine-responsive megaloblastic anemia in the Czech Republic, a rare form of monogenic diabetes mellitus: a novel mutation in the thiamine transporter SLC19A2 gene-intron 1 mutation c.204+2T>G.
Pomahačová R, Zamboryová J, Sýkora J, et al.
Pediatric diabetes 2017; (18(8)):844-847 doi:10.1111/pedi.12479.
PMID: 28004468 - 9
Early thiamine therapy in Rogers syndrome: Systematic review of hematologic, auditory and glycemic outcomes.
Upadhyay Z, Sudani S, Jain A
Bioinformation 2026; (22(1)):26-30 doi:10.6026/973206300220026.
PMID: 41960466 - 10
Thiamine responsive megaloblastic Anemia and deafness: A rare case of Roger's syndrome with successful hearing rehabilitation by cochlear implantation.
Marfatia H, Sahai A, Narkhede K, Sharma M
Journal of otology 2024; (19(3)):163-165 doi:10.1016/j.joto.2024.05.001.
PMID: 39735239 - 11
Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome.
Wu S, Yuan Z, Sun Z, et al.
American journal of medical genetics. Part A 2022; (188(3)):948-952 doi:10.1002/ajmg.a.62582.
PMID: 34821467 - 12
Could thiamine supplementation delay the progression of retinal dystrophy in Rogers syndrome?
Jung EH, Miltich M, Vidaurri-Martinez J, et al.
Ophthalmic genetics 2026; 1-5 doi:10.1080/13816810.2026.2736738.
PMID: 42773711 - 13
Arrhythmia in thiamine responsive megaloblastic anemia syndrome.
Argun M, Baykan A, Hatipoğlu N, et al.
The Turkish journal of pediatrics 2018; (60(3)):348-351.
PMID: 30511554 - 14
TRMA syndrome with a severe phenotype, cerebral infarction, and novel compound heterozygous SLC19A2 mutation: a case report.
Li X, Cheng Q, Ding Y, et al.
BMC pediatrics 2019; (19(1)):233 doi:10.1186/s12887-019-1608-2.
PMID: 31296181 - 15
Outcomes of End-User Testing of a Care Coordination Mobile App With Families of Children With Special Health Care Needs: Simulation Study.
Wong W, Ming D, Pateras S, et al.
JMIR formative research 2023; (7()):e43993 doi:10.2196/43993.
PMID: 37639303 - 16
Thiamine-Responsive Megaloblastic Anemia-Related Diabetes: Long-Term Clinical Outcomes in 23 Pediatric Patients From the DPV and SWEET Registries.
Warncke K, Prinz N, Iotova V, et al.
Canadian journal of diabetes 2021; (45(6)):539-545 doi:10.1016/j.jcjd.2020.11.006.
PMID: 33388275 - 17
Preferences for coordinated care for rare diseases: discrete choice experiment.
Morris S, Walton H, Simpson A, et al.
Orphanet journal of rare diseases 2024; (19(1)):332 doi:10.1186/s13023-024-03353-0.
PMID: 39252123
This page is for informational purposes only and does not constitute medical advice. Your child's care team should tailor specialist referrals, monitoring, medicines, and emergency plans to their needs.